Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Pazopanib Hydrochloride Patent Expiration

Pazopanib Hydrochloride was first introduced by Novartis Pharmaceuticals Corp in its drug Votrient on Oct 19, 2009. 5 different companies have introduced drugs containing Pazopanib Hydrochloride.


Pazopanib Hydrochloride Patents

Given below is the list of patents protecting Pazopanib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Votrient US7105530 Pyrimidineamines as angiogenesis modulators Oct 19, 2023

(Expired)

 Novartis
Votrient US7262203 Pyrimidineamines as angiogenesis modulators Dec 19, 2021

(Expired)

 Novartis
Votrient US8114885 Chemical compounds Dec 19, 2021

(Expired)

 Novartis


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pazopanib Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Pazopanib Hydrochloride.

Event Date Patent/Publication
Patent litigations
Expire Patent 18 Mar, 2024 US8114885
Maintenance Fee Reminder Mailed 02 Oct, 2023 US8114885
Payment of Maintenance Fee, 8th Year, Large Entity 02 Aug, 2019 US8114885
Payment of Maintenance Fee, 12th Year, Large Entity 14 Feb, 2019 US7262203
Payment of Maintenance Fee, 12th Year, Large Entity 01 Mar, 2018 US7105530
Email Notification 05 Jun, 2015 US8114885
Change in Power of Attorney (May Include Associate POA) 05 Jun, 2015 US8114885
Correspondence Address Change 04 Jun, 2015 US8114885
Email Notification 04 Jun, 2015 US7262203
Change in Power of Attorney (May Include Associate POA) 04 Jun, 2015 US7262203



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Pazopanib Hydrochloride Generics

Several generic applications have been filed for Pazopanib Hydrochloride. The first generic version for Pazopanib Hydrochloride was by Sun Pharmaceutical Industries Ltd and was approved on Oct 19, 2023. And the latest generic version is by Novugen Oncology Sdn Bhd and was approved on Apr 23, 2024.

Given below is the list of companies who have filed for Pazopanib Hydrochloride generic.


1. TEVA PHARMS INC

Teva Pharmaceuticals Inc has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 200MG BASE tablet Prescription ORAL AB Oct 19, 2023


2. APOTEX

Apotex Inc has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 200MG BASE tablet Prescription ORAL AB Oct 19, 2023


3. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 200MG BASE tablet Prescription ORAL AB Oct 19, 2023


4. NOVUGEN

Novugen Oncology Sdn Bhd has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Novugen.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 200MG BASE tablet Prescription ORAL AB Apr 23, 2024